CA2563687A1 - Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines - Google Patents

Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines Download PDF

Info

Publication number: CA2563687A1
Authority: CA; Canada
Prior art keywords: piperidinyl; carbonyl; dihydro; dibromo; amino
Prior art date: 2004-04-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002563687A

Other languages

English (en)

French (fr)

Inventor

Henri Doods

Klaus Rudolf

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim International GmbH

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-20

Filing date

2005-04-18

Publication date

2005-11-03

2004-04-20 Priority claimed from DE102004019736A external-priority patent/DE102004019736A1/de

2004-12-29 Priority claimed from DE102004063754A external-priority patent/DE102004063754A1/de

2005-04-18 Application filed by Individual filed Critical Individual

2005-11-03 Publication of CA2563687A1 publication Critical patent/CA2563687A1/en

Status Abandoned legal-status Critical Current

Links

229940127597 CGRP antagonist Drugs 0.000 title claims abstract description 52
239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 title claims abstract description 50
229940126570 serotonin reuptake inhibitor Drugs 0.000 title claims abstract description 44
239000003772 serotonin uptake inhibitor Substances 0.000 title claims abstract description 44
208000019695 Migraine disease Diseases 0.000 title claims abstract description 26
150000003839 salts Chemical class 0.000 claims abstract description 64
238000000034 method Methods 0.000 claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
206010019233 Headaches Diseases 0.000 claims abstract description 12
208000006561 Cluster Headache Diseases 0.000 claims abstract description 11
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 235
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
206010027599 migraine Diseases 0.000 claims description 17
-1 1-methyl-4-piperidinyl Chemical group 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 15
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
230000037396 body weight Effects 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 14
230000008569 process Effects 0.000 claims description 12
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 9
229960002866 duloxetine Drugs 0.000 claims description 9
230000002265 prevention Effects 0.000 claims description 8
206010027603 Migraine headaches Diseases 0.000 claims description 6
208000018912 cluster headache syndrome Diseases 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 5
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
238000007920 subcutaneous administration Methods 0.000 claims description 5
239000000969 carrier Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 3
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 3
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
229960001653 citalopram Drugs 0.000 claims description 3
229960004341 escitalopram Drugs 0.000 claims description 3
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 3
229960002464 fluoxetine Drugs 0.000 claims description 3
229960004038 fluvoxamine Drugs 0.000 claims description 3
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 3
150000004677 hydrates Chemical class 0.000 claims description 3
WKNXSXMQCRROEB-GDLZYMKVSA-N n-[(2r)-3-(4-amino-3,5-dibromophenyl)-1-oxo-1-(4-piperidin-1-ylpiperidin-1-yl)propan-2-yl]-4-(2,2-dioxo-1,4-dihydro-2$l^{6},1,3-benzothiadiazin-3-yl)piperidine-1-carboxamide Chemical compound C1=C(Br)C(N)=C(Br)C=C1C[C@H](C(=O)N1CCC(CC1)N1CCCCC1)NC(=O)N1CCC(N2S(NC3=CC=CC=C3C2)(=O)=O)CC1 WKNXSXMQCRROEB-GDLZYMKVSA-N 0.000 claims description 3
229960002296 paroxetine Drugs 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
229960002073 sertraline Drugs 0.000 claims description 3
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 3
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 3
229960003991 trazodone Drugs 0.000 claims description 3
125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
231100000869 headache Toxicity 0.000 abstract description 7
239000013543 active substance Substances 0.000 description 23
239000000203 mixture Substances 0.000 description 19
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
239000008188 pellet Substances 0.000 description 11
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000008101 lactose Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
239000008187 granular material Substances 0.000 description 7
239000002245 particle Substances 0.000 description 7
230000000697 serotonin reuptake Effects 0.000 description 7
230000000694 effects Effects 0.000 description 6
239000000843 powder Substances 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 5
239000002775 capsule Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
229940016286 microcrystalline cellulose Drugs 0.000 description 5
235000019813 microcrystalline cellulose Nutrition 0.000 description 5
239000008108 microcrystalline cellulose Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
229940069328 povidone Drugs 0.000 description 5
229940076279 serotonin Drugs 0.000 description 5
239000011162 core material Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000005557 antagonist Substances 0.000 description 3
238000001125 extrusion Methods 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
229960005168 croscarmellose Drugs 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
230000010339 dilation Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
239000003595 mist Substances 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229960000502 poloxamer Drugs 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229920003080 Povidone K 25 Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
ITIXDWVDFFXNEG-JHOUSYSJSA-N olcegepant Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCN(CC1)C=1C=CN=CC=1)NC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC(Br)=C(O)C(Br)=C1 ITIXDWVDFFXNEG-JHOUSYSJSA-N 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940100487 povidone k25 Drugs 0.000 description 1
239000012716 precipitator Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
210000001044 sensory neuron Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960003708 sumatriptan Drugs 0.000 description 1
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000000427 trigeminal ganglion Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229960001360 zolmitriptan Drugs 0.000 description 1
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

CA002563687A 2004-04-20 2005-04-18 Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines Abandoned CA2563687A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE102004019736.9		2004-04-20
DE102004019736A DE102004019736A1 (de)	2004-04-20	2004-04-20	Verwendung des CGRP-Antagonisten 1[N2[3,5 Dibrom-N-[[4(3,4 dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit (+)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamin zur Behandlung von Migräne
DE102004063754.7		2004-12-29
DE102004063754A DE102004063754A1 (de)	2004-12-29	2004-12-29	Verwendung eines CGRP-Antagonisten in Kombination mit einem Serotonin-Wiederaufnahme-Hemmer zur Behandlung von Migräne
PCT/EP2005/004076 WO2005102322A1 (de)	2004-04-20	2005-04-18	Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne

Publications (1)

Publication Number	Publication Date
CA2563687A1 true CA2563687A1 (en)	2005-11-03

Family

ID=34965481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002563687A Abandoned CA2563687A1 (en)	2004-04-20	2005-04-18	Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines

Country Status (4)

Country	Link
EP (1)	EP1740175A1 (de)
JP (1)	JP2007533685A (de)
CA (1)	CA2563687A1 (de)
WO (1)	WO2005102322A1 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3045182B1 (de)	2005-11-14	2018-03-07	Teva Pharmaceuticals International GmbH	Antagonistische antikörper gegen calcitonin gene-related peptide für behandlung von cluster-kopfschmerzen
US10323085B2 (en)	2008-03-04	2019-06-18	Teva Pharmaceuticals International Gmbh	Methods of treating fibromyalgia
US10392434B2 (en)	2016-09-23	2019-08-27	Teva Pharmaceuticals International Gmbh	Treating refractory migraine
US10519224B2 (en)	2014-03-21	2019-12-31	Teva Pharmaceuticals International Gmbh	Treating headache comprising administering an antibody to calcitonin gene-related peptide
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10597448B2 (en)	2009-08-28	2020-03-24	Teva Pharmaceuticals International Gmbh	Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7842808B2 (en)	2002-06-05	2010-11-30	Bristol-Myers Squibb Company	Anti-migraine spirocycles
US7220862B2 (en)	2002-06-05	2007-05-22	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
TW200524601A (en)	2003-12-05	2005-08-01	Bristol Myers Squibb Co	Heterocyclic anti-migraine agents
TW200533398A (en)	2004-03-29	2005-10-16	Bristol Myers Squibb Co	Novel therapeutic agents for the treatment of migraine
US7384931B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en)	2004-12-03	2008-11-11	Bristol-Myers Squibb Company	Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en)	2005-08-25	2010-11-16	Bristol-Myers Squibb Company	CGRP antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19911039A1 (de) *	1999-03-12	2000-09-14	Boehringer Ingelheim Pharma	Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) *	2001-08-17	2003-02-27	Boehringer Ingelheim Pharma	Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
EP1374870A1 (de) *	2002-06-24	2004-01-02	Rita Dobmeyer	Arzneimittel zur Behandlung oder Vorbeugung von Migräne
DE10314617A1 (de) *	2003-04-01	2004-10-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
AU2004252150B2 (en) *	2003-06-26	2008-11-20	Merck Sharp & Dohme Corp.	Benzodiazepine CGRP receptor antagonists

2005
- 2005-04-18 WO PCT/EP2005/004076 patent/WO2005102322A1/de not_active Application Discontinuation
- 2005-04-18 EP EP05735425A patent/EP1740175A1/de not_active Withdrawn
- 2005-04-18 CA CA002563687A patent/CA2563687A1/en not_active Abandoned
- 2005-04-18 JP JP2007508808A patent/JP2007533685A/ja active Pending

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3045182B1 (de)	2005-11-14	2018-03-07	Teva Pharmaceuticals International GmbH	Antagonistische antikörper gegen calcitonin gene-related peptide für behandlung von cluster-kopfschmerzen
US10329343B2 (en)	2005-11-14	2019-06-25	Teva Pharmaceuticals International Gmbh	Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
US10323085B2 (en)	2008-03-04	2019-06-18	Teva Pharmaceuticals International Gmbh	Methods of treating fibromyalgia
US10597448B2 (en)	2009-08-28	2020-03-24	Teva Pharmaceuticals International Gmbh	Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide
US10519224B2 (en)	2014-03-21	2019-12-31	Teva Pharmaceuticals International Gmbh	Treating headache comprising administering an antibody to calcitonin gene-related peptide
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US11555064B2 (en)	2014-03-21	2023-01-17	Teva Pharmaceuticals International Gmbh	Treating headache comprising administering an antibody to calcitonin gene-related peptide
US10392434B2 (en)	2016-09-23	2019-08-27	Teva Pharmaceuticals International Gmbh	Treating refractory migraine
US11028160B2 (en)	2016-09-23	2021-06-08	Teva Pharmaceuticals International Gmbh	Treating refractory migraine
US11028161B2 (en)	2016-09-23	2021-06-08	Teva Pharmaceuticals International Gmbh	Treating refractory migraine

Also Published As

Publication number	Publication date
JP2007533685A (ja)	2007-11-22
EP1740175A1 (de)	2007-01-10
WO2005102322A1 (de)	2005-11-03

Legal Events

Date	Code	Title	Description
2009-04-20	FZDE	Dead

Publication	Publication Date	Title
CA2563687A1 (en)	2005-11-03	Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
US20050233980A1 (en)	2005-10-20	CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
US6521609B1 (en)	2003-02-18	Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US20060142273A1 (en)	2006-06-29	Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine
JP6434416B2 (ja)	2018-12-05	ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
CA2378428C (en)	2009-10-20	Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
CN101616910A (zh)	2009-12-30	作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物
US20070249592A1 (en)	2007-10-25	Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
US20080176836A1 (en)	2008-07-24	Use of selected CGRP antagonists for combating menopausal hot flushes
KR20090020703A (ko)	2009-02-26	정신과 질환을 치료하기 위한 ｐ38 키나아제 억제제의 용도
AU2005205914A1 (en)	2005-08-04	Combination of organic compounds
DE102004063754A1 (de)	2006-07-13	Verwendung eines CGRP-Antagonisten in Kombination mit einem Serotonin-Wiederaufnahme-Hemmer zur Behandlung von Migräne
PL200537B1 (pl)	2009-01-30	Środek leczniczy do zapobiegania i leczenia schizofrenii oraz zastosowanie
CN117999073A (zh)	2024-05-07	纳多洛尔通过阻断抑制蛋白-2途径来治疗慢性阻塞性肺病的用途
EP1648466A1 (de)	2006-04-26	Verwendung von cgrp-antagonisten bei der behandlung und prävention von hitzewallungen bei patienten mit prostatakrebs
DE102004019736A1 (de)	2005-11-17	Verwendung des CGRP-Antagonisten 1[N2[3,5 Dibrom-N-[[4(3,4 dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit (+)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamin zur Behandlung von Migräne